Published in Front Immunol on October 10, 2016
Reactivating NK Cells in Treating Refractory Head and Neck Cancer (NKEXPHNC) | NCT02507154
Patient's Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers. Front Immunol (2017) 0.75
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Cetuximab for the treatment of colorectal cancer. N Engl J Med (2007) 13.39
Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst (2004) 10.61
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol (2001) 7.07
Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol (2004) 5.80
TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer (2010) 5.27
Natural killer cell signaling pathways. Science (2004) 4.00
Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene (2009) 3.90
Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 3.43
Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol (2007) 3.33
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03
Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A (2003) 2.71
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest (2011) 2.44
Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol (2004) 2.44
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol (2013) 2.33
Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res (2006) 1.92
Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res (2011) 1.91
RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res (2004) 1.83
Regulation of NK cell functions by TGF-beta 1. J Immunol (1995) 1.51
Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer (2009) 1.44
Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer. Clin Cancer Res (2016) 1.43
HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J (2005) 1.42
The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood (2006) 1.41
An update on the current and emerging targeted agents in metastatic colorectal cancer. Clin Colorectal Cancer (2011) 1.40
Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res (2011) 1.40
Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell (2016) 1.36
Early liaisons between cells of the innate immune system in inflamed peripheral tissues. Trends Immunol (2005) 1.35
The killer's kiss: the many functions of NK cell immunological synapses. Curr Opin Cell Biol (2008) 1.26
Dynamic and label-free monitoring of natural killer cell cytotoxic activity using electronic cell sensor arrays. J Immunol Methods (2006) 1.08
Effect of tumor cells and tumor microenvironment on NK-cell function. Eur J Immunol (2014) 1.08
Targeting natural killer cells in cancer immunotherapy. Nat Immunol (2016) 1.06
Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the γc cytokines and TGF-β1. Blood (2011) 1.04
Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function--implications for the adoptive immunotherapy of leukaemia. Clin Exp Immunol (2001) 1.02
Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages. PLoS One (2013) 1.02
NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J Immunol (2005) 1.01
Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets. J Immunol (2013) 1.00
Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. Br J Cancer (2009) 0.98
Tuning the threshold of natural killer cell responses. Curr Opin Immunol (2012) 0.96
Tumor induced inactivation of natural killer cell cytotoxic function; implication in growth, expansion and differentiation of cancer stem cells. J Cancer (2011) 0.94
Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer. J Transl Med (2013) 0.94
Natural killer cells: from basic research to treatments. Front Immunol (2011) 0.93
Natural killer cell-based therapies. F1000 Med Rep (2011) 0.93
Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors. Oncoimmunology (2014) 0.92
Cytolytic activity of human natural killer cell subpopulations isolated by four-color immunofluorescence flow cytometric cell sorting. Cytometry (1990) 0.91
NK cell dysfunction with down-regulated CD16 and up-regulated CD56 molecules in patients with esophageal squamous cell carcinoma. Dis Esophagus (2010) 0.91
Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma. Oncogene (2011) 0.90
Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients. Innate Immun (2012) 0.86
Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis. World J Gastroenterol (2016) 0.85
The TGF-β superfamily in dendritic cell biology. Cytokine Growth Factor Rev (2015) 0.82
Differential oncolytic effect of NK-enriched subsets in long-term interleukin-2 cultures. Lymphokine Cytokine Res (1992) 0.81
Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade. Eur J Immunol (2015) 0.79
Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity. Cancer Res (2016) 0.77
Establishing the reference intervals of NK cell functions in healthy adults. Hum Immunol (2016) 0.76